Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics.
Triple negative breast cancer refers to tumours lacking the expression of the three most used tumour markers, namely oestrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). These cancers are known to carry a more dismal prognosis than the other molecular subtypes. Whether a more aggressive local-regional treatment is warranted or not in patients with triple-negative breast cancer is still a matter of debate. Indeed there remain a number of grey zones with respect to the optimization of the extent and the timing of surgery and radiation therapy (RT) in this patient population, also in consideration of the significant heterogeneity in biological behaviour and response to treatment identified for these tumours. The objective of this review is to provide an insight into the biological and clinical behaviour of triple-negative breast cancers and revisit the most recent advances in their management, focussing on local-regional treatments.
Department of Radiation Oncology, Swiss Medical Network, Genolier, Geneva, Switzerland. Electronic address: jbernier@genolier.net.
Jacques
J
Bernier
Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Philip M P
PM
Poortmans
D005260:Female; D006801:Humans; D008408:Mastectomy / Q000379:methods*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods; D064726:Triple Negative Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy* / Q000601:surgery*
D011838:Radiation-Sensitizing Agents
Basal-like type breast cancer; Breast cancer; Breast conserving surgery; Mastectomy; Postoperative radiotherapy; Triple negative breast cancer